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Abstract
Conventional comparative genomic hybridization
(CGH) profiling of neuroblastomas has identified many
genomic aberrations, although the limited resolution
has precluded a precise localization of sequences of
interest within amplicons. To map high copy number
genomic gains in clinically matched stage IV neuro-
blastomas, CGH analysis using a 19,200- feature cDNA
microarray was used. A dedicated (freely available)
algorithm was developed for rapid in silico determina-
tion of chromosomal localizations of microarray cDNA
targets, and for generation of an ideogram-type profile
of copy number changes. Using these methodologies,
novel gene amplifications undetectable by chromosome
CGH were identified, and larger MYCN amplicon sizes
( in one tumor up to 6 Mb) than those previously
reported in neuroblastoma were identified. The genes
HPCAL1, LPIN1 /KIAA0188, NAG, and NSE1 /LOC151354
were found to be coamplified with MYCN. To determine
whether stage IV primary tumors could be further
subclassified based on their genomic copy number
profiles, hierarchical clustering was performed. Cluster
analysis of microarray CGH data identified three groups:
1) no amplifications evident, 2) a small MYCN amplicon
as the only detectable imbalance, and 3) a large MYCN
amplicon with additional gene amplifications. Applica-
tion of CGH to cDNA microarray targets will help to
determine both the variation of amplicon size and help
better define amplification-dependent and independent
pathways of progression in neuroblastoma.
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Introduction
Neuroblastoma is a pediatric malignancy with an incidence
rate in the U.S. of 1 in 100,000 children per year ( reviewed in
Ref. [1 ] ). About one third of neuroblastomas have gene
amplification, often observed cytogenetically as double
minute chromosomes (dmins), and occasionally as homo-
geneously staining regions (HSRs). Neuroblastoma is the
best example of a human tumor with intrinsic ability to
undergo high copy number gene amplification, which typically
involves a large and variable amount of DNA flanking the
MYCN (N-myc ) region of the genome at chromosome band
2p24 (reviewed in Ref. [2 ] ). Both the extent and complexity
of the amplified sequences associated with the MYCN
amplicon have been difficult to characterize using traditional
cytogenetic and molecular genetic mapping methods.
Recently, comparative genomic hybridization (CGH) to
metaphase chromosome targets [3 ] has increased our
understanding of the complexities of the amplicon structures
associated with MYCN amplification in neuroblastoma [2].
CGH analyses of neuroblastomas have identified genomic
imbalances commonly consisting ofMYCN amplification, 17q
gain, and deletions at 1p36, 3p, 4p, 9p, 11q, and 14q regions
[4–9]. However, the minimum resolution for determining
copy number gains is probably no less than 5 to 10 Mb, which
is a function of both copy number and amplicon size [3,10].
Consequently, this technique can only provide a starting point
for positional cloning studies, as the low resolution of
conventional cytogenetics prevents precise localization of
sequences of interest. Ideally, these limits are overcome
using high-resolution whole genome arrays spotted with
genomic clones (BACs, PACs, cosmids). However, this
method of determining the location and incidence of copy
number imbalances is not yet as widely available as
chromosome CGH and expression microarray technologies.
An emerging platform that addresses some of the short-
comings of chromosome CGH uses microarray expression
slides as target substrates for determining copy number [11].
Instead of using metaphase chromosomes, CGH is applied to
arrayed short sequences of DNA bound to glass slides and
probed with genomes of interest. With sufficient genetic
representation on the microarray, cDNA array CGH signifi-
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cantly increases resolution for identification of key genes in
regions of high copy number gain. However, because of the
small size and reduced complexity of the cDNA target
sequences, this approach may not have sufficient sensitivity
to reproducibly detect low copy number imbalances. In this
pilot study, we demonstrate the utility of cDNA array CGH for
characterizing high copy number gene amplification in stage
IV neuroblastoma tumors, to determine the diversity se-
quences coamplified with MYCN and the relative size of
the amplicon at 2p24 using a uniformly stratified patient
cohort with stage IV disease. Furthermore, we have de-
veloped dedicated software for microarray analysis and rapid
in silico determination of chromosomal localizations of
microarray cDNA targets that is essential for providing a
comprehensive ideogram-type schematic of copy number
changes. The use of these technologies in the analysis of
amplification in neuroblastoma highlights the advantages
and broad applicability of this system over conventional
chromosome CGH.
Materials and Methods
Patient Tissue Accrual and Polymerase Chain Reaction
(PCR) of MYCN Copy Number
Primary tumors were all clinically matched stage IV
neuroblastomas, collected from patients at the Hospital for
Sick Children. All samples were anonymous and were
collected under the guidelines of the Hospital for Sick
Children Research Ethics Board. The tumors were flash
frozen directly after surgical removal and stored in liquid
nitrogen. Genomic DNA from the tumor was extracted
following standard protocols [12]. The amplification status
of the MYCN gene was determined by standard quantitative
PCR analyses as previously described [13]. Briefly, samples
P1126, P1071, P1079, and P1008 were found to have
approximately 100 or more copies of MYCN. Sample P1061
showed intermediate 25 to 50 copies ofMYCN, and samples
D3025, D3060, D3077-95, and D3077-97 were observed
with less than 25 copies. Samples P1126, P1079, and P1071
were derived at different time points (pretreatment, post-
treatment, and posttreatment inguinal lymph node meta-
stasis, respectively) from the same patient. Table 1 lists the
clinical features of the patient cohort.
Chromosome CGH and Fluorescence In Situ Hybridization
(FISH)
Established protocols for CGH on human metaphase
chromosome spreads were followed [3]. Image capture and
analysis were performed using the Vysis PathVysion and
Karyotype software, respectively (Vysis, Downers Grove,
IL). Telomeric and centromeric regions were excluded in the
analyses due to the presence of highly repetitive genomic
sequences at these sites. Ten metaphases were analyzed
to create the final CGH profile with 99% confidence intervals.
Where possible, FISH assessment of MYCN copy number
in cytogenetic preparations from neuroblastoma primary
tumors was performed as previously described [13]. A
minimum of 100 interphase nuclei was evaluated in each
cytogenetic sample for assessing the MYCN copy number.
cDNA Array CGH
Microarrays used in this study [Human 19k2 microarray,
Clinical Genomics Centre (CGC), Toronto, Ontario, Can-
ada] contain a total of 19,200 features (Research Genetics,
Invitrogen, Huntsville, AL) including 18,980 human cDNAs
and 220 positive and negative control features. The features
of the 19k2 microarray are arranged on two glass slides
(parts A and B), each with 32 subgrids spotted over an
approximate area of 1836 mm2. All features are placed in
duplicate, for a total of 38,400 spots. A complete list of
the cDNA collection used for these arrays and protocols
used for array construction can be found at the University
Health Network CGC web site (http: //www.microarrays.ca).
It should be noted that some genes that have been reported
to be part of the MYCN amplicon, such as N-cym [14] and
DDX1 [15], are not presently on the current configuration of
the 19k2 microarray. Sequence verification studies being
performed by the CGC allowed us to identify by BLAST
analysis a small percentage of cDNAs contaminated with
mitochondrial DNA (mtDNA). Identification of such sequen-
ces has allowed us to make appropriate changes and filters
for our software suite (see below).
The procedure for cDNA array CGH is a modified version
of the protocol published by Pollack et al. [11], and reviewed
in Ref. [16]. Each microarray slide (part A and B) was
blocked under a glass coverslip for 1 hour at 378C with
blocking solution (3% BSA, 4 SSC, 0.1% Tween-20)
before hybridization with the denatured probe. Four micro-
Table 1. Clinical Information for the Patient Samples Used in This Study.
Patient sample Gender Age ( years ) Tumor stage Survival (months ) Primary site Shimada histology [ 51 ] Ploidy 1p Deletion
D3025 M 3.97 4 9.5 Adrenal Unfavorable Diploid Deleted
D3060 M 4.42 4 9.5 Adrenal Unfavorable Diploid Deleted
D3077 -95 M 1 4 9.57 Right adrenal N /A Diploid N /A
D3077 -97 M 3.98 4 15 Abdomen Unfavorable Aneuploid Deleted
P1061 M 1.79 4 14.83 Left adrenal Unfavorable Aneuploid Deleted
P1008 F 2.37 4 15.37 Right adrenal Unfavorable Near tetraploid Not deleted
P1126 M 1.96 4 14 Left adrenal Unfavorable Diploid Deleted
P1071 M 1.96 4 14 Left adrenal Unfavorable Diploid Deleted
P1079 M 1.96 4 14 Left adrenal Unfavorable Diploid Deleted
Note all samples were derived from stage IV tumors.
N/A, not available.
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grams each of high molecular weight tumor and normal
genomic DNA was separately digested with EcoRI for
2 hours, purified (Qiaquick PCR kit ), vacuum dried, and
resuspended in 25 l water. Random primer labeling was
performed using the Bioprime Labeling kit ( Invitrogen,
Carlsbad, CA) according to manufacturer’s instructions, with
modifications to directly incorporate Cy3- and Cy5-dCTP
(Amersham, Piscataway, NJ). The Cy3- and Cy5- labeled
products were suppressed with 30 g Cot-1 DNA (Invitro-
gen), 100 g yeast tRNA ( Invitrogen), and 20 g poly(dA-
dT) (Sigma-Aldrich, St. Louis, MO), loaded onto a microcon
30 filter (Amicon, Bedford, MA), and centrifuged for 20
minutes at 5000g. The sample was recovered with 60 l
hybridization buffer (3.4 SSC and 0.3% SDS), and
denatured at 1008C for 90 seconds. The probe was imme-
diately chilled on ice, and allowed to preanneal at 378C for
0.5 to 1 hour. The probe was divided and added to each
microarray slide (part A and B) under a glass coverslip and
sealed with rubber cement. Hybridization was at 378C for
16 to 20 hours in a moist chamber humidified with hybrid-
ization buffer. The microarrays were washed at 658C for
5 minutes in 2 SSC, 0.03% SDS, followed by successive
washes in 1 and 0.2 SSC at room temperature (5 minutes
each). After air drying, the slides were scanned using an
Axon GenePix 4000A confocal scanner and fluorescence
intensities were quantified with GenePix Pro 3.0 software
(Axon Instruments, Union City, CA). Replicate and reverse-
labeling experiments were performed for selected samples.
Control genomic DNAs used in these studies included three
cell lines with established levels of high copy number MYCN
amplifications, including the retinoblastoma cell line Y79, and
the neuroblastoma cell lines IMR32 and NUB-7 (American
Tissue Culture Collection, Rockville, MD).
Bioinformatics and Analyses
Custom software scripts were developed to update the
chromosome localizations for the cDNAs of the 19k2 micro-
array. However, any gene list having GenBank accession
and I.M.A.G.E. clone [17] identifiers can be updated with this
approach. The algorithm involved parsing NCBI UniGene
and MapViewer databases to identify up- to-date cytoband
localizations. Briefly, the UniGene database (build 147) was
retrieved ( ftp: // ftp.ncbi.nih.gov/ ) and used to update UniG-
ene identifiers in the gene list based on accession number.
Subsequently, the accession and updated UniGene identi-
fiers for each cDNA were cross-referenced to sequence
mapping data and additional cytoband information in the
MapViewer and UniGene databases, respectively. The infor-
mation updates for each cDNA in the gene list include the
chromosomal distance in megabases, the corresponding
cytoband (based on ISCN 800 level band resolution size
measurements; [18] ), and a qualitative assessment score of
mapping precision based on the concordance of the results
gathered from the databases. Updated gene lists for these
microarrays, as well as a more detailed description of the
update algorithm, can be found at the laboratory’s web site
Table 2. Genetic Representation of the 19k2 Microarray after Updating of Localization Information.
Number of clones
with position known
Number of clones
with position unknown
Total microarray
clones
Microarray percentage
representation
Actual genome
percentage
representation
Chromosome 1 638 1018 1656 8.7% 7.9%
Chromosome 2 532 593 1125 5.9% 7.8%
Chromosome 3 411 558 969 5.1% 6.8%
Chromosome 4 198 507 705 3.7% 6.3%
Chromosome 5 380 432 812 4.3% 6.0%
Chromosome 6 400 487 887 4.7% 5.7%
Chromosome 7 384 488 872 4.6% 5.2%
Chromosome 8 291 336 627 3.3% 4.7%
Chromosome 9 319 402 721 3.8% 4.4%
Chromosome 10 334 369 703 3.7% 4.4%
Chromosome 11 434 489 923 4.8% 4.4%
Chromosome 12 459 457 916 4.8% 4.5%
Chromosome 13 166 178 344 1.8% 3.6%
Chromosome 14 284 312 596 3.1% 3.3%
Chromosome 15 298 309 607 3.2% 3.2%
Chromosome 16 266 342 608 3.2% 2.8%
Chromosome 17 405 415 820 4.3% 2.8%
Chromosome 18 159 151 310 1.6% 2.7%
Chromosome 19 317 490 807 4.3% 2.2%
Chromosome 20 232 204 436 2.3% 2.2%
Chromosome 21 92 114 206 1.1% 1.4%
Chromosome 22 187 181 368 1.9% 1.5%
Chromosome X 211 327 538 2.8% 5.1%
Chromosome Y 8 4 12 0.1% 1.2%
Unknown – 2412 2412 12.7% –
Total 7405 11575 18980 100% 100%
For each chromosome, the number of clones with known and unknown positions is listed, as well as its total representation on the microarray. For comparison, the
last column identifies the total percentage size of each chromosome within the genome, based on ISCN chromosome size measurements [ 18 ]. Discrepancies
between the microarray and actual representations are due to genetic redundancy on the microarray, the large number of clones with completely unknown
positions, and that the percentage for actual chromosome genomic contribution includes non–coding sequences.
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(http: //www.utoronto.ca/cancyto/ ). Table 2 depicts the
genetic representation of the 19k2 microarrays.
To facilitate analysis of results from multiple 19k2 micro-
array experiments, custom software was also developed.
The software suite is currently comprised of four PC DOS-
based components: 1) normalize, 2) project, 3) clusterp, and
4) profiler. The normalize software normalizes quantified
Cy5 and Cy3 fluorescence intensities, with or without back-
ground subtraction, across the entire array as well as across
individual subgrids. Additionally, preceding normalization,
filters are applied to remove spots below user-specified
thresholds for fluorescence intensity, foreground- to-back-
ground ratio, and/or spot diameter size. After normalization
and filtering, duplicate spots from the microarray are
averaged together. Using project, two or more normalized
replicates of an experiment, including reverse- labelings, can
be grouped together as a project. Additionally, project also
groups together results from parts A and B of a 19k2
microarray experiment. The clusterp software uses selected
project files to generate output that can be read by the
Eisen Cluster software package (http: // rana.lbl.gov) for
two-dimensional hierarchical clustering [19,20]. Clustering
was performed on genes showing hybridization in 80% of
samples using an uncentered correlation similarity metric.
Finally, profiler uses the updated chromosome localization
information to generate composite chromosome plots of
normalized fluorescence intensity ratios from selected
projects, generating images analogous to karyotype profiles
from chromosome CGH. Note that only results for cDNA
sequences with known cytoband and megabase position are
plotted. To make microarray CGH methods more generally
accessible to the research community, this software suite
and the algorithms for automated cytoband and megabase
localization of microarray cDNA features are freely available
online (http: //www.utoronto.ca/cancyto/ ). All experimental
results are also available online as tab-delimited text files
(http: //www.utoronto.ca/cancyto/NB2003/ ).
Results
Optimization and Performance of cDNA Array CGH
The cDNA array CGH technique was optimized initially by
comparing genomic DNA from IMR32, a metastatic neuro-
blastoma cell line with known copy number changes, and
characterized by chromosome CGH (Figure 1A ), against a
normal reference. Replicate cDNA array CGH experiments
(n=4) including a reverse- labeling hybridization demon-
strated good reproducibility and the expected MYCN
amplification of sequences mapping to the 2p24 chromoso-
mal region. The distribution of normalized fluorescence
intensity ratios for all hybridization features (n=72,139 in
four hybridizations) was 0.94±0.25 (mean±1 SD), estab-
lishing a 99% confidence interval limit of 0.19 to 1.69. (Figure
1B ) shows the composite CGH genomic profile of IMR32 by
cDNA array CGH.
Figure 1. Validation of the cDNA array CGH technique. Genomic DNA from the neuroblastoma cell line IMR32 was used in both conventional CGH on metaphase
chromosomes ( inset, A ) and cDNA array CGH (B ). In the ideogram profiles generated for the cDNA array CGH results, the normalized fluorescence intensity ratios
from individual replicates ( n=4 ) are given in yellow, and their average is plotted in red. Note the profile for chromosome Y is not shown due to the low representation
of genes from this chromosome on the microarray. Chromosome CGH of IMR32 showed expected MYCN amplification at 2p24, with an additional amplification at
2p15 (A ). These changes were also observed by cDNA array CGH, but at higher resolution (B ). cDNA array CGH was able to determine that the gene amplification
at 2p15 corresponded to MEIS1, which was recently reported using other methods.
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To semiquantitate the chromosomal distributions and
relative levels of copy number imbalance by CGH using both
cDNA and metaphase targets, the MYCN normalized flu-
orescence intensity ratios was derived from a series of 12
neuroblastomas and cell lines against copy number meas-
urements determined by standard quantitative PCR and
Southern blot methods. Southern blot analyses of the
neuroblastoma cell lines IMR32 and NUB-7 [21], and the
Figure 2. Comparison of resolution of chromosome CGH (A ) and cDNA array CGH (B ) techniques for determining genomic amplifications in a neuroblastoma
patient P1071. Fluorescence in situ hybridization with labeled MYCN probe was used to verify copy number amplification of MYCN in interphase nuclei (C ). (A ) CGH
on metaphase chromosomes showed amplification along the distal short arm of chromosome 2, but due to the limited resolution of the technique was not able to
resolve the region to smaller than approximately 60 Mb (2pter –2p22 ). (B ) cDNA array CGH profile of genomic imbalances in the same patient ( n=3 replicates )
clearly delineated the 2p24 amplification to involve MYCN as well as other 2p24 genes in the vicinity of MYCN. Although it is expected that the technical issues
dealing with low detection sensitivity will be resolved in the future, this study has focused on discussion of genes showing dosage changes of greater than 25 copies.
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retinoblastoma cell line Y79 [22], have previously shown
MYCN to have 50, 100, and 50 copies, respectively. By
cDNA array CGH, the normalized fluorescence intensity
ratios for MYCN spots were 6.5, 11.2, and 5.2, for IMR32,
NUB-7, and Y79, respectively (not shown). Similarly,MYCN
normalized fluorescence intensity ratios for the patient
samples were approximately 10% of the corresponding
PCR measurement. Overall, there was good correlation
between the cDNA array CGH normalized fluorescence
intensity ratios, and the copy number determined by PCR or
Southern blot (R2=0.71). This analysis showed that with this
sensitivity of detection, deletions or copy number gains
below the level of 10 to 20 copies cannot be determined with
certainty. Most likely, this sensitivity limit arises because of
the small size of ( intronless) cDNA targets on the arrays
leading to basal background hybridization signals that mask
the small signals arising from lower copy number imbal-
ances. In contrast, multiple analyses ( including use of dye
switches) demonstrated that there was an excellent dynamic
range at higherMYCN copy number with good reproducibility
of copy number estimates, and with ratios that were
consistent with high copy number MYCN amplification.
cDNA Array CGH of Neuroblastoma Tissues
In the next series of experiments, amplification analysis
using IMR32 metaphase chromosome CGH was compared
to the profiles obtained using cDNA array CGH. Chromo-
some CGH showed two distinct regions of amplification on
chromosome 2p (Figure 1A ), with the most distal centering
onMYCN at 2p24, and the second more proximal location of
gene amplification was at 2p15. The analysis of IMR32 by
cDNA array CGH also identified these two amplification loci,
and more clearly resolved the putative genes subject to
amplification. At the 2p24 locus, theMYCN amplification was
clearly identified by microarray CGH. In addition, the gene
NSE1 was found to be coamplified within 1 Mb telomeric to
MYCN in IMR32. Interestingly another gene, DNMT3A,
which is situated nearly 10 Mb centromeric to MYCN, was
also observed to be amplified. It is noteworthy that CGH
applied to metaphase preparations was unable to differ-
entiate the size of the 2p24-p23 amplicon in IMR32 with
such precision.
The ratio analysis of the MEIS1 sequences on the cDNA
array clearly identified this gene in the cytoband 2p15 to be
subject to amplification (Figure 1B ). The MEIS1 amplifica-
tion was recently reported in IMR32 by others using different
methodologies [23,24]. The normalized fluorescence inten-
sity ratios of 5.24 and 6.85 from two distinct cDNA
sequences on the microarray representing MEIS1 would
predict between 50 and 70 copies. Furthermore, the
analyses also indicated that a currently unknown sequence
(GenBank accession N68286) within 15 kb telomeric to
MEIS1 was also coamplified. These novel findings concern-
ing the fine structure of the amplicons mapping to 2p in
IMR32 have not been previously reported.
Microarray CGH was performed using genomic DNA
derived from nine newly diagnosed neuroblastoma tumor
samples. Of the nine studied, one (P1071) was subjected to
both chromosome and cDNA array CGH, and MYCN ampli-
fication was also confirmed by interphase FISH (Figure 2,
A–C ). The cDNA array CGH resolved the 2p24 MYCN
amplification boundaries to include the genes HPCAL1 and
KIAA0188 /LPIN1 that map to a 6-Mb flanking region
telomeric of MYCN. The copy number gain of 22q shown
by chromosome CGH was indicated to be due to amplifica-
tion of the gene ST13 at 22q13 by cDNA array CGH
(Figure 2, A and B, respectively). The same larger MYCN
amplicon at 2p24 was also observed in samples from the
same patient, P1126 and P1079, but not in any of the other
patient samples. In samples P1008 and P1061, the only
amplification was MYCN; however, sample P1008 showed
additionally amplification of a flanking unknown sequence
(accession T79037) which by BLAST sequence analysis is
reported to be the gene NAG. The remaining DNA samples
did not show detectable amplification of MYCN, or of any
other genetic loci. A summary of the amplified genes and
sequences identified by cDNA array CGH in neuroblastomas
is given in Table 3.
Unsupervised two-dimensional hierarchical clustering
analysis was then performed on the cDNA array CGH data
Table 3. Genes Showing High Copy Gain Common to all Patient Samples Identified by cDNA Array CGH and Hierarchical Clustering, Some of Which are Novel
and Previously Unreported in Neuroblastomas.
GenBank accession of clone UniGene ID Symbol Cytoband Approximate
megabase from pter
Function /Evidence
H19826 Hs.3618 HPCAL1 2p24 9.7 Calcium -binding protein with similarity to
hippocalin, expressed only in the brain.
R77965, H23930, N45520 Hs.81412 LPIN1 /KIAA0188 2p24 11.8 Gene responsible for fatty liver dystrophy in
mice, candidate gene for human lipodystrophy.
T79037 – unknown 2p24 13.6 Sequence has as very high similarity to genomic
clone RP11 -516B14 containing NAG gene.
T65604 Hs.260855 NSE1 /LOC151354 2p24 14.15 Novel member of the H - rev107 protein family.
R52824 Hs.25960 MYCN 2p24 15.45 Oncogene commonly amplified in
neuroblastomas and retinoblastomas.
H03349 Hs.241565 DNMT3A 2p24 24.92 Gene transcriptional silencing by
de novo DNA methylation.
N68286 Hs.109391 unknown 2p15 70.81 Unknown.
N95243, AA034934 Hs.170177 MEIS1 2p15 70.83 Novel homeobox gene.
Only clones that have been sequence verified are listed.
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as a class discovery procedure for categorizing DNA copy
number relationships between the neuroblastomas. The idea
of clustering gene expression to detect functional relation-
ships is conceptually similar to analyzing DNA copy number
relationships in a group of tumors to empirically delineate
classes of sequences subject to amplification. Hierarchical
clustering of similarly amplified sequences may suggest
close linkage of genes on common amplicon structures. In
support of this idea, unsupervised hierarchical clustering was
able to provide clear class distinction based on copy number
amplification in neuroblastoma. As shown in Figure 3, the
majority of primary tumor DNA samples were shown to
branch together within the dendogram, away from the cell
line IMR32. Within the cluster of primary tumor samples, the
MYCN low- or non–amplified samples clustered closely
together (D3025, D3060, D3077-95, D3077-97). Samples
P1008 and P1061 coclustered separately in this group, likely
due to the high copy number of MYCN. Samples from the
same patient (P1126, P1079) clustered together, and apart
from the other patient samples, presumably due to the higher
MYCN amplification and largerMYCN amplicon. The sample
P1071 was derived from an undifferentiated neuroblastoma
inguinal lymph node metastasis that has additional gene
amplifications not present in DNA isolated from the more
differentiated samples from this same patient (P1126,
P1079).
In summary, hierarchical clustering permitted classifica-
tion of this sample set of stage IV neuroblastoma patient
tumors into three groups based on pattern of copy number
changes: 1) no amplifications evident (D3025, D3060,
D3077-95, D3077-97); 2) MYCN amplification as the only
evident genomic copy number change, or a small MYCN
amplicon (P1061, P1008); and 3) a large MYCN amplicon
with additional gene amplifications (P1126, P1071, P1079).
These findings are summarized in Figure 4.
Discussion
In this study, high-density cDNA microarray CGH profiling of
10 neuroblastomas was used to determine the precise chro-
mosomal locations of gene amplifications in these tumors.
There have been previous CGH studies of neuroblastoma
using conventional metaphase chromosome preparations
[4–9], but this analysis represents the first microarray
genomic profiling of amplifications in neuroblastoma.
CGH analysis of metaphase chromosomes has enabled
genome-wide detection of DNA copy number imbalances
[3]. However, the relatively low resolution of chromosome
CGH means that further experiments are necessary to map
amplicon structures and to provide detailed positional
mapping of amplified sequences of interest. Although CGH
studies using genomic DNA microarrays (BAC, PAC,
cosmid) have recently been published [25–31], these
arrays are not yet generally available and/or at present do
not have sufficient genomic coverage and therefore reso-
lution for screening. Recently, several studies have shown
the utility of cDNA microarray CGH for studying gene copy
changes. Initially demonstrated by Pollack et al. [11],
Kauraniemi et al. [32] have used a 636- feature chromo-
some 17-specific cDNA array for identifying gene copy
amplifications by CGH in breast cancer cell lines. However,
to date, there have been few reports documenting successful
application of microarray CGH using cDNA targets.
To assess the sensitivity of cDNA array CGH analysis,
PCR-quantified MYCN copy number was compared to
amplification levels determined by cDNA array CGH. This
comparison demonstrated that a minimum sensitivity of 10 to
20 copies could be obtained reproducibly, but that lower copy
number alterations would escape detection. Improved sensi-
tivity may be obtained using a recently published tyramide-
based amplification protocol to augment the fluorescent
signal [33]. However, one major limitation of this system is
that it is not currently adaptable to two-color CGH.
After assessment of the relative sensitivity of high-density
cDNA array CGH for profiling amplifications, the MYCN
amplicon structure was determined using a panel of neuro-
Figure 3. Relationships between the neuroblastomas as defined by
unsupervised two -dimensional hierarchical clustering of gene dosage change
patterns derived from cDNA array CGH results. The full cluster results are
provided as supplementary information online ( http: // www.utoronto.ca /
cancyto /NB2003 / ).
Figure 4. Categorization of neuroblastomas based on hierarchical clustering
of cDNA array CGH results, as represented by changes on chromosome 2.
Groups 1, 2, and 3 are defined as having no detectable genomic ampli-
fications; MYCN amplification as the only evident genomic copy number
change, or a small MYCN amplicon; and MYCN amplification with additional
amplification of a number of the genes in the vicinity of the MYCN locus;
respectively.
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blastomas. It was previously reported that the MYCN
amplicon can range in size from 350 kb to 1 Mb [2]. These
conclusions were based largely on enzymatic restriction
mapping [34] or metaphase and chromatin fiber FISH
mapping [21] techniques using different probes to define
amplicon boundaries. However, with the advent of cDNA
microarray technology combined with biological information
from the Human Genome Project, a more precise examina-
tion of MYCN amplicon size and complexity is now possible.
Our results suggest that the MYCN amplicon can be much
larger than 1 Mb, and in fact we have observed up to 6 Mb in
samples P1071, P1079, and P1126.
Altogether, the genes mapping to chromosome band
2p24 that were observed to be coamplified with MYCN
included: hippocalcin- like 1 (HPCAL1 ), lipin 1 (LPIN1 /
KIAA0188 ), neuroblastoma amplified gene (NAG ), and an
unannotated gene (NSE1 /LOC151354 ). Hippocalcin - like 1
has high similarity to hippocalcin on chromosome 1, which
has been identified as a calcium sensor with neuronal tissue
expression specificity [35,36]. Lipin 1 encodes a novel
nuclear protein that although its function is currently un-
known, in mouse, it is reported to be required for regulation of
normal adipose tissue development [37,38]. NAG has
previously been observed to be part of the MYCN amplicon,
although its function is still as yet unknown [39]. The
GenBank entry (accession AJ417080) for NSE1 (unpub-
lished) indicates this gene to be a novel member of the H-
rev107 protein family, whose members include the 2A
protein in picornaviruses and the cellular retinoic acid
receptor responder 3 (RARRES3 /TIG3 ) protein [40,41],
with putative cellular antiproliferative activity. Except for
NAG, recruitment of these genes into the MYCN amplicon
has not been previously reported.
In addition to those genes mapping to 2p24, amplification
was also detected at other genomic locations in isolated
tumors. The gene ST13 (suppressor of tumorigenicity 13),
whichmaps to 22q13 and is reported to be an Hsp70-binding
protein during steroid receptor assembly [42], was observed
to be amplified in one tumor. Amplification of another gene
DNA (cytosine-5) methyltransferase 3 alpha (DNMT3A ),
which is 10 Mb centromeric to MYCN, was observed in
IMR32. This gene belongs to a family of DNA methyltrans-
ferases (DNMTs) and has a role in transcriptional regulation
of gene silencing through de novo methylation of DNA CpG
islands [43]. It has been reported that overexpression of
DNMT3A is associated with aberrant methylation profiles in
tumors as compared to normal cells [43,44]. Interestingly,
amplification of mtDNA sequences was commonly observed
in the tumors in the study group (data not shown). This
observation suggests that increased numbers of mitochon-
dria may be a feature of neuroblastoma oncogenesis. In
keeping with this idea, it is interesting that mtDNA ampli-
fication has been reported previously in other tumors in-
cluding gliomas [45–47].
To better subclassify the genomic profiles obtained in the
analyses, an unsupervised hierarchical clustering approach
was used to delineate three distinct groups of neuro-
blastomas within the study group, identified by: 1) no evident
copy number change; 2) MYCN amplification as the only
evident genomic copy number change, or a small MYCN
amplicon; and 3) MYCN amplification concomitant with
additional gene amplifications, or a large MYCN amplicon.
This is interesting, given that all the samples represent
clinically similar stage IV tumors. Recently, other studies
have also applied clustering algorithms to subtype tumors on
the basis of the patterns of imbalances present in genomic
profiling data [31,48]. In one study, self -organizing maps
were used to categorize stage pT2N0 prostate carcinomas
analyzed by chromosome CGH [48]. Similarly, the applica-
tion of a support vector machine algorithm was recently
described for subclassifying dedifferentiated and pleomor-
phic liposarcomas using genomic microarray CGH data [31].
Interestingly, the study also demonstrated that the genomic
profiling approach was more robust in delineating tumor
subclasses than the corresponding expression profiling
method [31].
In conclusion, cDNA array CGH can be readily used to
identify and map gene amplifications at high resolution. A
diversity of amplification patterns including larger more com-
plex MYCN amplicon structures was detected in a series of
neuroblastomas drawn from a group with equivalent ad-
vanced stage disease. Studies in model systems have
demonstrated multiple and redundant phylogenetically con-
served repair pathways involved in maintenance of genome
stability ( reviewed in Refs. [49,50] ). Unrepaired, DNA dam-
age results in accumulating genomic rearrangements and
ensuing genomic instability, is thought to underlie the acqui-
sition of gene amplification. In the present study, cDNA array
analysis identified three diverse patterns of genomic profile
associated with advanced stage neuroblastoma that (within
the limitations of the study group size) did not appear to
impact on disease course. This observation suggests that
the inherent biological differences in genomic stability within
neuroblastoma do not appear to directly impact on disease
course. Presently, high-resolution, high- throughput assays
such as microarray CGH can be used for detailed analysis of
genomic instability in other human tumors. Furthermore, the
dedicated algorithms developed for this study are freely
available for improved applications of microarray analyses,
based on information provided by the chromosomal band
locations of the microarray cDNA sequences. In the future,
increased technique sensitivity and refinements to the
bioinformatics of genomic profiling will greatly facilitate an
improved understanding of the biology that underlies the
complex patterns of genomic imbalance identified by CGH
methods.
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